1h Free Analyst Time
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function.Speak directly to the analyst to clarify any post sales queries you may have.
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 3, 1, 13 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Musculoskeletal Disorders, Respiratory, Women's Health, Gastrointestinal, Genetic Disorders and Undisclosed which include indications Colorectal Cancer, Solid Tumor, Autoimmune Disorders, Gastric Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Rectal Cancer, Triple-Negative Breast Cancer (TNBC), Unspecified Cancer, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Endometriosis, Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Liver Cancer, Metastatic Colorectal Cancer, Osteoarthritis, Pain, Pancreatic Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Allergies, Asthma, Bladder Cancer, Bone Defects, Cancer Pain, Cervical Cancer, Colon Cancer, Delirium, Endometrial Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Inflammation, Inflammatory Bowel Disease, Inflammatory Pain, Metastatic Pancreatic Cancer, Neuroinflammation, Osteoarthritis Pain, Osteogenesis Imperfecta, Osteoporosis, Pneumonia, Prostate Cancer, Rheumatoid Arthritis, Sarcomas, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Unspecified.
The latest report Prostaglandin E2 Receptor EP4 Subtype - Drugs In Development, 2022, outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
- The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Overview
- Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Companies Involved in Therapeutics Development
- Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drug Profiles
- Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Dormant Products
- Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Discontinued Products
- Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Product Development Milestones
- Featured News & Press Releases
- Apr 27, 2022: Tempest announces poster presentations at the upcoming 2022 ASCO Annual Meeting
- Apr 08, 2022: Tempest presents promising preclinical data on TPST-1495 at the 2022 AACR Annual Meeting
- Nov 18, 2021: Tempest announces first patient dosed with TPST-1495 in Combination with Pembrolizumab
- Nov 12, 2021: Tempest presents data supporting the dual mechanism of TPST-1495 as an optimal approach for targeting the prostaglandin pathway in cancer
- Nov 08, 2021: Tempest Further bolsters patent portfolio with issuance of multiple patents for TPST-1495
- Oct 01, 2021: Tempest announces presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
- Sep 08, 2021: Adlai Nortye announces first patient dosed in phase Ia clinical trial of AN0025 in combination with atezolizumab for advanced solid tumors
- Aug 24, 2020: Adlai Nortye announces first patient dosed in phase 1b clinical trial of AN0025 (EP4 Antagonist) in combination with Merck's KEYTRUDA (pembrolizumab) for advanced solid tumors
- Jan 30, 2020: Tempest Therapeutics announces FDA clearance of investigational new drug application for TPST-1495 and welcomes new investors
- Sep 30, 2019: Adlai Nortye presents encouraging phase 1b study data of AN0025 at ESMO 2019
- Sep 30, 2019: Adlai Nortye presents encouraging phase 1b study data of AN0025 (an Oral EP4 Antagonist) for locally advanced rectal cancer at ESMO 2019
- May 07, 2019: Kyn Therapeutics strengthens leadership team with key appointments
- Dec 20, 2018: Kyn Therapeutics and Merck begin Phase Ib/I trials of ARY-007
- Jul 19, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Is Approved in China
- Apr 17, 2018: Japan Patent Office Granted AskAt a Cartilage Disease Use Patent of EP4 Antagonist
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by AskAt Inc, 2022
- Pipeline by Domain Therapeutics SA, 2022
- Pipeline by Draconis Pharma SL, 2022
- Pipeline by Eisai Co Ltd, 2022
- Pipeline by Exalys Therapeutics Inc, 2022
- Pipeline by GSK plc, 2022
- Pipeline by Gurus BioPharm Inc, 2022
- Pipeline by Ionova Life Science Co Ltd, 2022
- Pipeline by Kaken Pharmaceutical Co Ltd, 2022
- Pipeline by Medibiofarma SL, 2022
- Pipeline by Mesentech Inc, 2022
- Pipeline by NB Health Laboratory Co Ltd, 2022
- Pipeline by Ono Pharmaceutical Co Ltd, 2022
- Pipeline by Oscotec Inc, 2022
- Pipeline by RaQualia Pharma Inc, 2022
- Pipeline by Rottapharm Biotech Srl, 2022
- Pipeline by Shanghai Bioray Laboratory Inc, 2022
- Pipeline by Sosei Group Corp, 2022
- Pipeline by Tempest Therapeutics Inc, 2022
- Pipeline by Teon Therapeutics Inc, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AskAt Inc
- Domain Therapeutics SA
- Draconis Pharma SL
- Eisai Co Ltd
- Exalys Therapeutics Inc
- GSK plc
- Gurus BioPharm Inc
- Ionova Life Science Co Ltd
- Kaken Pharmaceutical Co Ltd
- Medibiofarma SL
- Mesentech Inc
- NB Health Laboratory Co Ltd
- Ono Pharmaceutical Co Ltd
- Oscotec Inc
- RaQualia Pharma Inc
- Rottapharm Biotech Srl
- Shanghai Bioray Laboratory Inc
- Sosei Group Corp
- Tempest Therapeutics Inc
- Teon Therapeutics Inc
